» Articles » PMID: 15782138

Differential Roles for the Coactivators CBP and P300 on TCF/beta-catenin-mediated Survivin Gene Expression

Overview
Journal Oncogene
Date 2005 Mar 23
PMID 15782138
Citations 166
Authors
Affiliations
Soon will be listed here.
Abstract

The inhibitor of apoptosis (IAP) protein survivin is highly expressed in cancers, but not in normal differentiated tissues. TCF/beta-catenin signaling has been reported to participate in the regulation of survivin transcription in colon cancer. We have recently characterized ICG-001, a small molecule specific inhibitor of the beta-catenin/Creb-binding protein (CBP) interaction. Inhibition of the beta-catenin/CBP interaction represses a subset of TCF/beta-catenin-mediated transcription. ICG-001 potently inhibits survivin gene transcription and expression. ICG-001-mediated downregulation of survivin expression enhanced caspase-3 activity and apoptosis, which was rescued by overexpression of wild type but not mutant (C84A) survivin. Small interfering RNA and genetic reduction of CBP also decreased survivin expression. Chromatin immunoprecipitation assay confirmed that CBP is the crucial coactivator for TCF/beta-catenin-mediated survivin transcription. Furthermore, ICG-001-induced recruitment of p300 to the survivin promoter led to concomitant recruitment of SUMO-1, HDAC6 and PML proteins, which have been associated with transcriptional repression. These findings demonstrate that CBP and p300 play very distinct roles in survivin gene transcription.

Citing Articles

The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?.

Spallotta F, Illi B Biomedicines. 2024; 12(11).

PMID: 39595195 PMC: 11591585. DOI: 10.3390/biomedicines12112631.


PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.

Yang K, Fu K, Zhang H, Wang X, To K, Yang C Mol Cancer. 2024; 23(1):209.

PMID: 39342174 PMC: 11438308. DOI: 10.1186/s12943-024-02129-1.


Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?.

de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prevostel C Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065798 PMC: 11279613. DOI: 10.3390/ph17070949.


β-catenin/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer.

Reed E, Jankowski S, Spinella A, Noonan V, Haddad R, Nomoto K Transl Res. 2023; 260:46-60.

PMID: 37353110 PMC: 10527608. DOI: 10.1016/j.trsl.2023.05.007.


TCF1/LEF1 triggers Wnt-dependent chemokine/cytokine-induced inflammation and cadherin pathways to drive T-ALL cell migration.

Zhao P, Sun L, Zhao C Biochem Biophys Rep. 2023; 34:101457.

PMID: 36942321 PMC: 10024088. DOI: 10.1016/j.bbrep.2023.101457.